Pharsight

Fusilev generic

Fusilev is an anti-cancer drug owned by Acrotech. It contains the active ingredient levoleucovorin calcium. The drug was first authorized for market use on 07 March, 2008.

When will Fusilev generic be available?

The patent for Fusilev, termed US6500829 & titled 'Substantially pure diastereoisomers of tetrahydrofolate derivatives', has expired on March 7, 2022. Therefore, it's generic version is possible to be released after March 7, 2022.

Fusilev uses

Fusilev, containing levoleucovorin calcium, is used for treating cancer. It works by reducing the side effects of a certain medication (methotrexate) while allowing it to work effectively.

Fusilev patent expiration

Fusilev holds a single patent titled 'Substantially pure diastereoisomers of tetrahydrofolate derivatives', which has recently expired on March 7, 2022. This expired patent sets the stage for the release of Fusilev generic. Below are the details of the patent:

Litigations filed on Fusilev

Fusilev dosage

Want to ask something?